Middle East respiratory syndrome coronavirus ORF4b protein inhibits type I interferon production through both cytoplasmic and nuclear targets.
Identifieur interne : 001360 ( PubMed/Curation ); précédent : 001359; suivant : 001361Middle East respiratory syndrome coronavirus ORF4b protein inhibits type I interferon production through both cytoplasmic and nuclear targets.
Auteurs : Yang Yang [République populaire de Chine] ; Fei Ye [République populaire de Chine] ; Na Zhu [République populaire de Chine] ; Wenling Wang [République populaire de Chine] ; Yao Deng [République populaire de Chine] ; Zhengdong Zhao [République populaire de Chine] ; Wenjie Tan [République populaire de Chine]Source :
- Scientific reports [ 2045-2322 ] ; 2015.
Descripteurs français
- KwdFr :
- Cellules HeLa (virologie), Coronavirus du syndrome respiratoire du Moyen-Orient (pathogénicité), Cytoplasme (métabolisme), Cytoplasme (virologie), Facteur-3 de régulation d'interféron (génétique), Facteur-3 de régulation d'interféron (métabolisme), Facteur-7 de régulation d'interféron (métabolisme), Humains, Hélicase IFIH1 inductrice de l'interféron (génétique), Hélicase IFIH1 inductrice de l'interféron (métabolisme), I-kappa B Kinase (métabolisme), Interactions hôte-pathogène, Interféron bêta (génétique), Interféron bêta (métabolisme), Noyau de la cellule (métabolisme), Noyau de la cellule (virologie), Phosphorylation, Protein-Serine-Threonine Kinases (métabolisme), Protéine-58 à domaine DEAD (génétique), Protéine-58 à domaine DEAD (métabolisme), Protéines adaptatrices de la transduction du signal (métabolisme), Protéines virales (génétique), Protéines virales (métabolisme), Protéines virales (pharmacologie).
- MESH :
- génétique : Facteur-3 de régulation d'interféron, Hélicase IFIH1 inductrice de l'interféron, Interféron bêta, Protéine-58 à domaine DEAD, Protéines virales.
- métabolisme : Cytoplasme, Facteur-3 de régulation d'interféron, Facteur-7 de régulation d'interféron, Hélicase IFIH1 inductrice de l'interféron, I-kappa B Kinase, Interféron bêta, Noyau de la cellule, Protein-Serine-Threonine Kinases, Protéine-58 à domaine DEAD, Protéines adaptatrices de la transduction du signal, Protéines virales.
- pathogénicité : Coronavirus du syndrome respiratoire du Moyen-Orient.
- pharmacologie : Protéines virales.
- virologie : Cellules HeLa, Cytoplasme, Noyau de la cellule.
- Humains, Interactions hôte-pathogène, Phosphorylation.
English descriptors
- KwdEn :
- Adaptor Proteins, Signal Transducing (metabolism), Cell Nucleus (metabolism), Cell Nucleus (virology), Cytoplasm (metabolism), Cytoplasm (virology), DEAD Box Protein 58 (genetics), DEAD Box Protein 58 (metabolism), HeLa Cells (virology), Host-Pathogen Interactions, Humans, I-kappa B Kinase (metabolism), Interferon Regulatory Factor-3 (genetics), Interferon Regulatory Factor-3 (metabolism), Interferon Regulatory Factor-7 (metabolism), Interferon-Induced Helicase, IFIH1 (genetics), Interferon-Induced Helicase, IFIH1 (metabolism), Interferon-beta (genetics), Interferon-beta (metabolism), Middle East Respiratory Syndrome Coronavirus (pathogenicity), Phosphorylation, Protein-Serine-Threonine Kinases (metabolism), Viral Proteins (genetics), Viral Proteins (metabolism), Viral Proteins (pharmacology).
- MESH :
- chemical , genetics : DEAD Box Protein 58, Interferon Regulatory Factor-3, Interferon-Induced Helicase, IFIH1, Interferon-beta, Viral Proteins.
- chemical , metabolism : Adaptor Proteins, Signal Transducing, DEAD Box Protein 58, I-kappa B Kinase, Interferon Regulatory Factor-3, Interferon Regulatory Factor-7, Interferon-Induced Helicase, IFIH1, Interferon-beta, Protein-Serine-Threonine Kinases, Viral Proteins.
- metabolism : Cell Nucleus, Cytoplasm.
- pathogenicity : Middle East Respiratory Syndrome Coronavirus.
- chemical , pharmacology : Viral Proteins.
- virology : Cell Nucleus, Cytoplasm, HeLa Cells.
- Host-Pathogen Interactions, Humans, Phosphorylation.
Abstract
Middle East respiratory syndrome coronavirus (MERS-CoV) is a novel and highly pathogenic human coronavirus and has quickly spread to other countries in the Middle East, Europe, North Africa and Asia since 2012. Previous studies have shown that MERS-CoV ORF4b antagonizes the early antiviral alpha/beta interferon (IFN-α/β) response, which may significantly contribute to MERS-CoV pathogenesis; however, the underlying mechanism is poorly understood. Here, we found that ORF4b in the cytoplasm could specifically bind to TANK binding kinase 1 (TBK1) and IκB kinase epsilon (IKKε), suppress the molecular interaction between mitochondrial antiviral signaling protein (MAVS) and IKKε, and inhibit IFN regulatory factor 3 (IRF3) phosphorylation and subsequent IFN-β production. Further analysis showed that ORF4b could also inhibit IRF3 and IRF7-induced production of IFN-β, whereas deletion of the nuclear localization signal of ORF4b abrogated its ability to inhibit IRF3 and IRF7-induced production of IFN-β, but not IFN-β production induced by RIG-I, MDA5, MAVS, IKKε, and TBK-1, suggesting that ORF4b could inhibit the induction of IFN-β in both the cytoplasm and nucleus. Collectively, these results indicate that MERS-CoV ORF4b inhibits the induction of type I IFN through a direct interaction with IKKε/TBK1 in the cytoplasm, and also in the nucleus with unknown mechanism. Viruses have evolved multiple strategies to evade or thwart a host's antiviral responses. A novel human coronavirus (HCoV), Middle East respiratory syndrome coronavirus (MERS-CoV), is distinguished from other coronaviruses by its high pathogenicity and mortality. However, virulence determinants that distinguish MERS-CoV from other HCoVs have yet to be identified. MERS-CoV ORF4b antagonizes the early antiviral response, which may contribute to MERS-CoV pathogenesis. Here, we report the identification of the interferon (IFN) antagonism mechanism of MERS-CoV ORF4b. MERS-CoV ORF4b inhibits the production of type I IFN through a direct interaction with IKKε/TBK1 in the cytoplasm, and also in the nucleus with unknown mechanism. These findings provide a rationale for the novel pathogenesis of MERS-CoV as well as a basis for developing a candidate therapeutic against this virus.
DOI: 10.1038/srep17554
PubMed: 26631542
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001360
Links to Exploration step
pubmed:26631542Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Middle East respiratory syndrome coronavirus ORF4b protein inhibits type I interferon production through both cytoplasmic and nuclear targets.</title>
<author><name sortKey="Yang, Yang" sort="Yang, Yang" uniqKey="Yang Y" first="Yang" last="Yang">Yang Yang</name>
<affiliation wicri:level="1"><nlm:affiliation>Key Laboratory of Medical Virology, Ministry of Health; National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Key Laboratory of Medical Virology, Ministry of Health; National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Ye, Fei" sort="Ye, Fei" uniqKey="Ye F" first="Fei" last="Ye">Fei Ye</name>
<affiliation wicri:level="1"><nlm:affiliation>Key Laboratory of Medical Virology, Ministry of Health; National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Key Laboratory of Medical Virology, Ministry of Health; National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Zhu, Na" sort="Zhu, Na" uniqKey="Zhu N" first="Na" last="Zhu">Na Zhu</name>
<affiliation wicri:level="1"><nlm:affiliation>Key Laboratory of Medical Virology, Ministry of Health; National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Key Laboratory of Medical Virology, Ministry of Health; National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Wang, Wenling" sort="Wang, Wenling" uniqKey="Wang W" first="Wenling" last="Wang">Wenling Wang</name>
<affiliation wicri:level="1"><nlm:affiliation>Key Laboratory of Medical Virology, Ministry of Health; National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Key Laboratory of Medical Virology, Ministry of Health; National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Deng, Yao" sort="Deng, Yao" uniqKey="Deng Y" first="Yao" last="Deng">Yao Deng</name>
<affiliation wicri:level="1"><nlm:affiliation>Key Laboratory of Medical Virology, Ministry of Health; National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Key Laboratory of Medical Virology, Ministry of Health; National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Zhao, Zhengdong" sort="Zhao, Zhengdong" uniqKey="Zhao Z" first="Zhengdong" last="Zhao">Zhengdong Zhao</name>
<affiliation wicri:level="1"><nlm:affiliation>Key Laboratory of Pathogen System Biology, Ministry of Health; Institute of Pathogen Biology, Chinese Academy of Medical Sciences, Beijing, 100176, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Key Laboratory of Pathogen System Biology, Ministry of Health; Institute of Pathogen Biology, Chinese Academy of Medical Sciences, Beijing, 100176</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Tan, Wenjie" sort="Tan, Wenjie" uniqKey="Tan W" first="Wenjie" last="Tan">Wenjie Tan</name>
<affiliation wicri:level="1"><nlm:affiliation>Key Laboratory of Medical Virology, Ministry of Health; National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Key Laboratory of Medical Virology, Ministry of Health; National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2015">2015</date>
<idno type="RBID">pubmed:26631542</idno>
<idno type="pmid">26631542</idno>
<idno type="doi">10.1038/srep17554</idno>
<idno type="wicri:Area/PubMed/Corpus">001360</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001360</idno>
<idno type="wicri:Area/PubMed/Curation">001360</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001360</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Middle East respiratory syndrome coronavirus ORF4b protein inhibits type I interferon production through both cytoplasmic and nuclear targets.</title>
<author><name sortKey="Yang, Yang" sort="Yang, Yang" uniqKey="Yang Y" first="Yang" last="Yang">Yang Yang</name>
<affiliation wicri:level="1"><nlm:affiliation>Key Laboratory of Medical Virology, Ministry of Health; National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Key Laboratory of Medical Virology, Ministry of Health; National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Ye, Fei" sort="Ye, Fei" uniqKey="Ye F" first="Fei" last="Ye">Fei Ye</name>
<affiliation wicri:level="1"><nlm:affiliation>Key Laboratory of Medical Virology, Ministry of Health; National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Key Laboratory of Medical Virology, Ministry of Health; National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Zhu, Na" sort="Zhu, Na" uniqKey="Zhu N" first="Na" last="Zhu">Na Zhu</name>
<affiliation wicri:level="1"><nlm:affiliation>Key Laboratory of Medical Virology, Ministry of Health; National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Key Laboratory of Medical Virology, Ministry of Health; National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Wang, Wenling" sort="Wang, Wenling" uniqKey="Wang W" first="Wenling" last="Wang">Wenling Wang</name>
<affiliation wicri:level="1"><nlm:affiliation>Key Laboratory of Medical Virology, Ministry of Health; National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Key Laboratory of Medical Virology, Ministry of Health; National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Deng, Yao" sort="Deng, Yao" uniqKey="Deng Y" first="Yao" last="Deng">Yao Deng</name>
<affiliation wicri:level="1"><nlm:affiliation>Key Laboratory of Medical Virology, Ministry of Health; National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Key Laboratory of Medical Virology, Ministry of Health; National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Zhao, Zhengdong" sort="Zhao, Zhengdong" uniqKey="Zhao Z" first="Zhengdong" last="Zhao">Zhengdong Zhao</name>
<affiliation wicri:level="1"><nlm:affiliation>Key Laboratory of Pathogen System Biology, Ministry of Health; Institute of Pathogen Biology, Chinese Academy of Medical Sciences, Beijing, 100176, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Key Laboratory of Pathogen System Biology, Ministry of Health; Institute of Pathogen Biology, Chinese Academy of Medical Sciences, Beijing, 100176</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Tan, Wenjie" sort="Tan, Wenjie" uniqKey="Tan W" first="Wenjie" last="Tan">Wenjie Tan</name>
<affiliation wicri:level="1"><nlm:affiliation>Key Laboratory of Medical Virology, Ministry of Health; National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Key Laboratory of Medical Virology, Ministry of Health; National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206</wicri:regionArea>
</affiliation>
</author>
</analytic>
<series><title level="j">Scientific reports</title>
<idno type="eISSN">2045-2322</idno>
<imprint><date when="2015" type="published">2015</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adaptor Proteins, Signal Transducing (metabolism)</term>
<term>Cell Nucleus (metabolism)</term>
<term>Cell Nucleus (virology)</term>
<term>Cytoplasm (metabolism)</term>
<term>Cytoplasm (virology)</term>
<term>DEAD Box Protein 58 (genetics)</term>
<term>DEAD Box Protein 58 (metabolism)</term>
<term>HeLa Cells (virology)</term>
<term>Host-Pathogen Interactions</term>
<term>Humans</term>
<term>I-kappa B Kinase (metabolism)</term>
<term>Interferon Regulatory Factor-3 (genetics)</term>
<term>Interferon Regulatory Factor-3 (metabolism)</term>
<term>Interferon Regulatory Factor-7 (metabolism)</term>
<term>Interferon-Induced Helicase, IFIH1 (genetics)</term>
<term>Interferon-Induced Helicase, IFIH1 (metabolism)</term>
<term>Interferon-beta (genetics)</term>
<term>Interferon-beta (metabolism)</term>
<term>Middle East Respiratory Syndrome Coronavirus (pathogenicity)</term>
<term>Phosphorylation</term>
<term>Protein-Serine-Threonine Kinases (metabolism)</term>
<term>Viral Proteins (genetics)</term>
<term>Viral Proteins (metabolism)</term>
<term>Viral Proteins (pharmacology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Cellules HeLa (virologie)</term>
<term>Coronavirus du syndrome respiratoire du Moyen-Orient (pathogénicité)</term>
<term>Cytoplasme (métabolisme)</term>
<term>Cytoplasme (virologie)</term>
<term>Facteur-3 de régulation d'interféron (génétique)</term>
<term>Facteur-3 de régulation d'interféron (métabolisme)</term>
<term>Facteur-7 de régulation d'interféron (métabolisme)</term>
<term>Humains</term>
<term>Hélicase IFIH1 inductrice de l'interféron (génétique)</term>
<term>Hélicase IFIH1 inductrice de l'interféron (métabolisme)</term>
<term>I-kappa B Kinase (métabolisme)</term>
<term>Interactions hôte-pathogène</term>
<term>Interféron bêta (génétique)</term>
<term>Interféron bêta (métabolisme)</term>
<term>Noyau de la cellule (métabolisme)</term>
<term>Noyau de la cellule (virologie)</term>
<term>Phosphorylation</term>
<term>Protein-Serine-Threonine Kinases (métabolisme)</term>
<term>Protéine-58 à domaine DEAD (génétique)</term>
<term>Protéine-58 à domaine DEAD (métabolisme)</term>
<term>Protéines adaptatrices de la transduction du signal (métabolisme)</term>
<term>Protéines virales (génétique)</term>
<term>Protéines virales (métabolisme)</term>
<term>Protéines virales (pharmacologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>DEAD Box Protein 58</term>
<term>Interferon Regulatory Factor-3</term>
<term>Interferon-Induced Helicase, IFIH1</term>
<term>Interferon-beta</term>
<term>Viral Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Adaptor Proteins, Signal Transducing</term>
<term>DEAD Box Protein 58</term>
<term>I-kappa B Kinase</term>
<term>Interferon Regulatory Factor-3</term>
<term>Interferon Regulatory Factor-7</term>
<term>Interferon-Induced Helicase, IFIH1</term>
<term>Interferon-beta</term>
<term>Protein-Serine-Threonine Kinases</term>
<term>Viral Proteins</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Facteur-3 de régulation d'interféron</term>
<term>Hélicase IFIH1 inductrice de l'interféron</term>
<term>Interféron bêta</term>
<term>Protéine-58 à domaine DEAD</term>
<term>Protéines virales</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Cell Nucleus</term>
<term>Cytoplasm</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Cytoplasme</term>
<term>Facteur-3 de régulation d'interféron</term>
<term>Facteur-7 de régulation d'interféron</term>
<term>Hélicase IFIH1 inductrice de l'interféron</term>
<term>I-kappa B Kinase</term>
<term>Interféron bêta</term>
<term>Noyau de la cellule</term>
<term>Protein-Serine-Threonine Kinases</term>
<term>Protéine-58 à domaine DEAD</term>
<term>Protéines adaptatrices de la transduction du signal</term>
<term>Protéines virales</term>
</keywords>
<keywords scheme="MESH" qualifier="pathogenicity" xml:lang="en"><term>Middle East Respiratory Syndrome Coronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="pathogénicité" xml:lang="fr"><term>Coronavirus du syndrome respiratoire du Moyen-Orient</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Protéines virales</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Viral Proteins</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Cellules HeLa</term>
<term>Cytoplasme</term>
<term>Noyau de la cellule</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Cell Nucleus</term>
<term>Cytoplasm</term>
<term>HeLa Cells</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Host-Pathogen Interactions</term>
<term>Humans</term>
<term>Phosphorylation</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Humains</term>
<term>Interactions hôte-pathogène</term>
<term>Phosphorylation</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Middle East respiratory syndrome coronavirus (MERS-CoV) is a novel and highly pathogenic human coronavirus and has quickly spread to other countries in the Middle East, Europe, North Africa and Asia since 2012. Previous studies have shown that MERS-CoV ORF4b antagonizes the early antiviral alpha/beta interferon (IFN-α/β) response, which may significantly contribute to MERS-CoV pathogenesis; however, the underlying mechanism is poorly understood. Here, we found that ORF4b in the cytoplasm could specifically bind to TANK binding kinase 1 (TBK1) and IκB kinase epsilon (IKKε), suppress the molecular interaction between mitochondrial antiviral signaling protein (MAVS) and IKKε, and inhibit IFN regulatory factor 3 (IRF3) phosphorylation and subsequent IFN-β production. Further analysis showed that ORF4b could also inhibit IRF3 and IRF7-induced production of IFN-β, whereas deletion of the nuclear localization signal of ORF4b abrogated its ability to inhibit IRF3 and IRF7-induced production of IFN-β, but not IFN-β production induced by RIG-I, MDA5, MAVS, IKKε, and TBK-1, suggesting that ORF4b could inhibit the induction of IFN-β in both the cytoplasm and nucleus. Collectively, these results indicate that MERS-CoV ORF4b inhibits the induction of type I IFN through a direct interaction with IKKε/TBK1 in the cytoplasm, and also in the nucleus with unknown mechanism. Viruses have evolved multiple strategies to evade or thwart a host's antiviral responses. A novel human coronavirus (HCoV), Middle East respiratory syndrome coronavirus (MERS-CoV), is distinguished from other coronaviruses by its high pathogenicity and mortality. However, virulence determinants that distinguish MERS-CoV from other HCoVs have yet to be identified. MERS-CoV ORF4b antagonizes the early antiviral response, which may contribute to MERS-CoV pathogenesis. Here, we report the identification of the interferon (IFN) antagonism mechanism of MERS-CoV ORF4b. MERS-CoV ORF4b inhibits the production of type I IFN through a direct interaction with IKKε/TBK1 in the cytoplasm, and also in the nucleus with unknown mechanism. These findings provide a rationale for the novel pathogenesis of MERS-CoV as well as a basis for developing a candidate therapeutic against this virus. </div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26631542</PMID>
<DateCompleted><Year>2016</Year>
<Month>12</Month>
<Day>13</Day>
</DateCompleted>
<DateRevised><Year>2018</Year>
<Month>11</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>5</Volume>
<PubDate><Year>2015</Year>
<Month>Dec</Month>
<Day>03</Day>
</PubDate>
</JournalIssue>
<Title>Scientific reports</Title>
<ISOAbbreviation>Sci Rep</ISOAbbreviation>
</Journal>
<ArticleTitle>Middle East respiratory syndrome coronavirus ORF4b protein inhibits type I interferon production through both cytoplasmic and nuclear targets.</ArticleTitle>
<Pagination><MedlinePgn>17554</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/srep17554</ELocationID>
<Abstract><AbstractText>Middle East respiratory syndrome coronavirus (MERS-CoV) is a novel and highly pathogenic human coronavirus and has quickly spread to other countries in the Middle East, Europe, North Africa and Asia since 2012. Previous studies have shown that MERS-CoV ORF4b antagonizes the early antiviral alpha/beta interferon (IFN-α/β) response, which may significantly contribute to MERS-CoV pathogenesis; however, the underlying mechanism is poorly understood. Here, we found that ORF4b in the cytoplasm could specifically bind to TANK binding kinase 1 (TBK1) and IκB kinase epsilon (IKKε), suppress the molecular interaction between mitochondrial antiviral signaling protein (MAVS) and IKKε, and inhibit IFN regulatory factor 3 (IRF3) phosphorylation and subsequent IFN-β production. Further analysis showed that ORF4b could also inhibit IRF3 and IRF7-induced production of IFN-β, whereas deletion of the nuclear localization signal of ORF4b abrogated its ability to inhibit IRF3 and IRF7-induced production of IFN-β, but not IFN-β production induced by RIG-I, MDA5, MAVS, IKKε, and TBK-1, suggesting that ORF4b could inhibit the induction of IFN-β in both the cytoplasm and nucleus. Collectively, these results indicate that MERS-CoV ORF4b inhibits the induction of type I IFN through a direct interaction with IKKε/TBK1 in the cytoplasm, and also in the nucleus with unknown mechanism. Viruses have evolved multiple strategies to evade or thwart a host's antiviral responses. A novel human coronavirus (HCoV), Middle East respiratory syndrome coronavirus (MERS-CoV), is distinguished from other coronaviruses by its high pathogenicity and mortality. However, virulence determinants that distinguish MERS-CoV from other HCoVs have yet to be identified. MERS-CoV ORF4b antagonizes the early antiviral response, which may contribute to MERS-CoV pathogenesis. Here, we report the identification of the interferon (IFN) antagonism mechanism of MERS-CoV ORF4b. MERS-CoV ORF4b inhibits the production of type I IFN through a direct interaction with IKKε/TBK1 in the cytoplasm, and also in the nucleus with unknown mechanism. These findings provide a rationale for the novel pathogenesis of MERS-CoV as well as a basis for developing a candidate therapeutic against this virus. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yang</LastName>
<ForeName>Yang</ForeName>
<Initials>Y</Initials>
<AffiliationInfo><Affiliation>Key Laboratory of Medical Virology, Ministry of Health; National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, China.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Shenzhen Key Laboratory of Pathogen and Immunity, Shenzhen Third People's Hospital, Shenzhen, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Ye</LastName>
<ForeName>Fei</ForeName>
<Initials>F</Initials>
<AffiliationInfo><Affiliation>Key Laboratory of Medical Virology, Ministry of Health; National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Zhu</LastName>
<ForeName>Na</ForeName>
<Initials>N</Initials>
<AffiliationInfo><Affiliation>Key Laboratory of Medical Virology, Ministry of Health; National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Wang</LastName>
<ForeName>Wenling</ForeName>
<Initials>W</Initials>
<AffiliationInfo><Affiliation>Key Laboratory of Medical Virology, Ministry of Health; National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Deng</LastName>
<ForeName>Yao</ForeName>
<Initials>Y</Initials>
<AffiliationInfo><Affiliation>Key Laboratory of Medical Virology, Ministry of Health; National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Zhao</LastName>
<ForeName>Zhengdong</ForeName>
<Initials>Z</Initials>
<AffiliationInfo><Affiliation>Key Laboratory of Pathogen System Biology, Ministry of Health; Institute of Pathogen Biology, Chinese Academy of Medical Sciences, Beijing, 100176, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Tan</LastName>
<ForeName>Wenjie</ForeName>
<Initials>W</Initials>
<AffiliationInfo><Affiliation>Key Laboratory of Medical Virology, Ministry of Health; National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, China.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2015</Year>
<Month>12</Month>
<Day>03</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>Sci Rep</MedlineTA>
<NlmUniqueID>101563288</NlmUniqueID>
<ISSNLinking>2045-2322</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D048868">Adaptor Proteins, Signal Transducing</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C494232">IRF3 protein, human</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C494234">IRF7 protein, human</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D050838">Interferon Regulatory Factor-3</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D050839">Interferon Regulatory Factor-7</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C505371">VISA protein, human</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014764">Viral Proteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>77238-31-4</RegistryNumber>
<NameOfSubstance UI="D016899">Interferon-beta</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="D017346">Protein-Serine-Threonine Kinases</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="C403191">TBK1 protein, human</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 2.7.11.10</RegistryNumber>
<NameOfSubstance UI="D051550">I-kappa B Kinase</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 3.6.1.-</RegistryNumber>
<NameOfSubstance UI="C452820">DDX58 protein, human</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 3.6.1.-</RegistryNumber>
<NameOfSubstance UI="C452815">IFIH1 protein, human</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 3.6.4.13</RegistryNumber>
<NameOfSubstance UI="D000071457">DEAD Box Protein 58</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 3.6.4.13</RegistryNumber>
<NameOfSubstance UI="D000072640">Interferon-Induced Helicase, IFIH1</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D048868" MajorTopicYN="N">Adaptor Proteins, Signal Transducing</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002467" MajorTopicYN="N">Cell Nucleus</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003593" MajorTopicYN="N">Cytoplasm</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000071457" MajorTopicYN="N">DEAD Box Protein 58</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006367" MajorTopicYN="N">HeLa Cells</DescriptorName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D054884" MajorTopicYN="N">Host-Pathogen Interactions</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D051550" MajorTopicYN="N">I-kappa B Kinase</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D050838" MajorTopicYN="N">Interferon Regulatory Factor-3</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D050839" MajorTopicYN="N">Interferon Regulatory Factor-7</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000072640" MajorTopicYN="N">Interferon-Induced Helicase, IFIH1</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016899" MajorTopicYN="N">Interferon-beta</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D065207" MajorTopicYN="N">Middle East Respiratory Syndrome Coronavirus</DescriptorName>
<QualifierName UI="Q000472" MajorTopicYN="Y">pathogenicity</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017346" MajorTopicYN="N">Protein-Serine-Threonine Kinases</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014764" MajorTopicYN="N">Viral Proteins</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year>
<Month>07</Month>
<Day>10</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2015</Year>
<Month>11</Month>
<Day>02</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2015</Year>
<Month>12</Month>
<Day>4</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2015</Year>
<Month>12</Month>
<Day>4</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2016</Year>
<Month>12</Month>
<Day>15</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>epublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">26631542</ArticleId>
<ArticleId IdType="pii">srep17554</ArticleId>
<ArticleId IdType="doi">10.1038/srep17554</ArticleId>
<ArticleId IdType="pmc">PMC4668369</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Nat Immunol. 2005 Oct;6(10):981-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16127453</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2008 May;82(9):4471-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18305050</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2003 May 15;348(20):1967-76</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12690091</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2003 Dec 18;349(25):2431-41</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14681510</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2005 Jun;79(12):7673-81</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15919920</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell. 2005 Sep 9;122(5):669-82</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16125763</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2005 Oct 20;437(7062):1167-72</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16177806</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2006 Apr;80(7):3567-81</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16537625</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2006 May 12;312(5775):879-82</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16690858</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2006 Oct;80(19):9667-75</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16973571</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virus Res. 2006 Dec;122(1-2):20-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16965829</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2007 Jan;81(2):548-57</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17108024</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2007 Feb 6;104(6):1853-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17267598</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2007 May;81(10):5315-24</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17344288</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2007 May;81(10):5091-101</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17344289</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biol Chem. 2008 May 23;283(21):14269-76</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18362155</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2009 Feb;83(3):1465-73</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19019954</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2009 Apr;83(7):3069-77</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19153231</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Host Microbe. 2009 May 8;5(5):439-49</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19454348</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biol Chem. 2009 Jun 12;284(24):16202-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19380580</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2009 Jul;83(13):6689-705</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19369340</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Interferon Cytokine Res. 2009 Sep;29(9):549-57</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19708812</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2009 Nov;83(21):11166-74</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19692472</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2010 May;84(9):4619-29</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20181693</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2010 Aug;84(16):8051-61</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20519382</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Gen Virol. 2011 Sep;92(Pt 9):2153-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21632562</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Opin Virol. 2012 Jun;2(3):264-75</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22572391</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Euro Surveill. 2012;17(40):20290</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23078800</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2012 Nov 8;367(19):1814-20</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23075143</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Med Virol. 2013 Jan;85(1):71-82</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23096996</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2012 Dec 13;492(7428):166-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23235854</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Immunology. 2013 Mar;138(3):190-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23173987</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS Pathog. 2013 Mar;9(3):e1003231</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23555247</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2013 May;87(9):5300-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23449793</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Sci Rep. 2013;3:1686</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23594967</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2013 Jun;87(12):6604-14</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23552422</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Gen Virol. 2013 Aug;94(Pt 8):1749-60</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23620378</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2013 Aug 24;382(9893):694-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23831141</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>MBio. 2013;4(5):e00650-13</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24023385</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antiviral Res. 2013 Sep;99(3):409-16</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23796981</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2013 Oct 1;110(40):16157-62</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24043791</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2013 Nov;87(22):12489-95</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24027320</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Protein Cell. 2013 Dec;4(12):951-61</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24318862</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Gen Virol. 2014 Mar;95(Pt 3):614-26</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24362959</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2014 Mar;88(6):3455-63</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24403580</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Gen Virol. 2014 Apr;95(Pt 4):874-82</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24443473</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2014 May;88(9):4866-76</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24522921</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Protein Cell. 2014 May;5(5):369-81</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24622840</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 2014 Sep 15;193(6):3080-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25135833</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2014;9(9):e107654</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25233083</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biol Chem. 2014 Dec 12;289(50):34667-82</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25320088</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Respir Med. 2015 Jul;3(7):509-10</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26050550</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2007 Jul;81(13):7011-21</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17442719</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS Pathog. 2007 Aug 10;3(8):e109</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17696607</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2007 Nov;81(21):11620-33</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17715225</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biol Chem. 2007 Nov 2;282(44):32208-21</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17761676</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Gen Virol. 2008 Jan;89(Pt 1):1-47</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18089727</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS Pathog. 2008 Jan;4(1):e13</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18225953</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Opin Immunol. 2008 Feb;20(1):17-22</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18272355</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virology. 2003 Mar 15;307(2):386-95</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12667806</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001360 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 001360 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= MersV1 |flux= PubMed |étape= Curation |type= RBID |clé= pubmed:26631542 |texte= Middle East respiratory syndrome coronavirus ORF4b protein inhibits type I interferon production through both cytoplasmic and nuclear targets. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:26631542" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \ | NlmPubMed2Wicri -a MersV1
![]() | This area was generated with Dilib version V0.6.33. | ![]() |